ExaneConsumer Ingredients Seminar



Similar documents
GDChVCW Konferenz February 28, 2013

Clariant continues on profitable growth path in 2013

Ludwigshafen, February 25, 2014

DISCOVER ASCOM S EXCITING BUSINESS FRITZ MUMENTHALER, CEO

Investors Presentation JANUARY 2015

Midyear Presentation market strategy

Commerzbank German Investment Seminar. Dr. Jürgen Köhler, CEO New York. January 2016

We add value as one company

We add value as one company

Financial Summary. Key Figures

i:fao Acquisition Investor Presentation April 3 rd, Amadeus IT Group SA

An Overview of the Global Hair and Skin Care Market

Shell Technology Webcast Friday 18 th August Technologies driving new fuels

Kemira well underway to return to profitable growth Kemira Capital Markets Day Wolfgang Büchele President and CEO

Global Growth Opportunities

Stabilus at a glance. April 2014

H Results. 12 August 2015

Speech of the Board of Management. General Shareholders Meeting, 9 June 2015

Chasing growth in a constrained environment

Clariant. BU ICS Engineering & Aviation

Value Creation through Transformation of Business Models

H Earning Results JULY 30 TH, 2014

THE WAY TO MAKE IT. Results 2013 and Outlook Agenda. 26 March Results Focus and outlook 2014 Discussion

Disclaimer: Forward Looking Statements

Clariant International Graduate Program WE RE SET TO GROW, AND WE D LIKE YOU TO JOIN US

Business Unit Advanced Industrial Intermediates A strong and stable player in chemical intermediates

Second Quarter 2015 Investor Conference Call

Commerzbank German Investment Seminar. 9 January 2012

FY2010 Results Presentation. 23 March 2011

Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015

Brenntag AG Analyst Round Table 2014

News Release. Master Builders Solutions launched in South Africa. New global brand bundles products and solutions for the construction industry

Development of the Client-Focused, Capital-Efficient Business Model

MEDIA RELEASE SIKA WITH STRONG GROWTH IN EMERGING MARKETS

INVESTOR PRESENTATION HALF YEAR 2012

Q2 and Half-Year 2010 Results

Tender offer to acquire. June 1, 2011

Our results at a glance

Swiss Equity conference zürich

2013 Half Year Results

34 th Annual J. P. Morgan Healthcare Conference. January 11 th -13 th, 2016 San Francisco

How To Improve Profits At Dismana

Ontex Q3 2015: Trading in line with Company expectations and full year outlook reiterated

Financial Translation. Pierre Courduroux Senior Vice President and Chief Financial Officer

ANALYST PRESENTATION 9M 2011 November 9, 2011

PIERRE JEAN SIVIGNON FINANCIAL. Deputy Chief Executive Officer, Chief Financial Officer RESULTS

March 5, First Quarter Conference Call

Fourth Quarter 2015 Conference Call

2014 Full Year Results

Earnings Release Q1 FY 2016 October 1 to December 31, 2015

Financial Information

Half year results 2011

Deutsche Bank 17th Annual European Leveraged Finance Conference. June 14, 2013 London

2013 Third Quarter Review October 25,

J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015

Investor Day. Group Strategy. Jean-Pascal Tricoire Chairman & CEO. February 20, 2014

Morgan Stanley European MedTech & Services Conference

Statement by Kasper Rorsted Chairman of the Management Board Conference-Call November 11, 2015, a.m.

Health Care Worldwide. Citi - European Credit Conference September 24, London

Three growth models. By Jean Berg Senior Vice President, Estin & Co

Global Supply. 17 November 2011

Partnership for Polymer Intermediates & Composite Resins

Acquisition of GEKA GmbH

FATTY ALCOHOLS. Rofanol

STAR CONFERENCE 2015 Milan

How To Profit From Brambles

Hitachi Announces Progress of 2015 Mid-term Management Plan

2013 Second Quarter Review July 26,

Announcement of FY2010-FY2011 Medium-Term Management Plan, Frontier e Enhancing Corporate Value on the World Stage, Shaping the Future -

A Leading Global Health Care Group

The need for action drivers of change

Second Quarter and First Half 2015 Trading Update

Third quarter results 2012

August 11, Q Earnings Presentation

Forward Looking Statement

Company announcement from Vestas Wind Systems A/S

Protection notice / Copyright notice

A Leading Global Health Care Group

GLOBAL BANKING & MARKETS

Ahlstrom. The global source for fiber-based materials. Blue Chip Seminar, September 7, 2006 CEO, Jukka Moisio

How international expansion is a driver of performance for insurers in uncertain times

How To Invest In Panin Life

UBS Global Financials Conference

Differentiation and profitable growth in a changing environment

H RESULTS. July 30, 2015

ONFERENCE CONFERENCE ANNUAL RESULTS

Be ONE: Our strategy in the current environment. Guidance 2010

1Q16 Earnings Release. April 28 th 2016 LG Electronics

Transcription:

ExaneConsumer Ingredients Seminar LONDON, 16 MAY 2013, DR. RALF ZERRER Public Ralf Zerrer BU ICS 16.05.2013

2 Disclaimer This presentation contains certain statements that are neither reported financial results nor other historical information. This presentation also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.

3 Clariant at a glance BUSINESS UNITS Sales 2012: CHF 6 038 million REGIONAL MARKETS Sales 2012: CHF 6 038 million SALES (CHF m) 2012 6 038 + 8 % CA 12% ICS 24% MB 19% PIG 15% North America 236 / +2% Europe 37% Europe, Middle East & Africa 699 / 0% Middle East Asia &/ Pacific Africa 349 / +1% 9% Asia/ Pacific 23% Latin America 225 / +12% 2011* 5 571* EBITDA (CHF m) before exceptionals 2012 802-4 % 2011* 835* MARGIN 2012: 13.3 % 2011: 15 % FM 11% ADD 1 7% OMS 12% ADD = Additives / FM = Functional Materials / CA= Catalysts / ICS = Industrial & Consumer Specialties / MB = Masterbatches / PIG = Pigments / OMS = Oil & Mining Services North America 16% 1 Additives includes part of the business unit Emulsions, which is not in scope of discontinued operations Latin America 15% EBIT (CHF m) before exceptionals 2012 531-15% 2011* 624* MARGIN 2012: 8.8 % 2011: 11.2 % * Restated due to discontinued operations

4 Focus activities on four Business Areas reporting structure as of Q1 2013 Care Chemicals Catalysis & Energy Natural Resources Plastics & Coatings Personal Care Catalysts Oil Services Additives Industrial Care Energy Storage Mining Solutions Pigments Home Care Refinery Services Masterbatches Crop Care Functional Minerals Industrial Biotechnology Water Treatment Food & Feed excl. Paper Specialties, Textile Chemicals, Emulsions Detergents & Intermediates, Leather Services

BU Industrial & Consumer Specialties Public Ralf Zerrer BU ICS 16.05.2013

6 Key facts BU Industrial and Consumer Specialties ICS one of the largest providers of specialty chemicals and application solutions for consumer care and industrial markets. Combining market knowledge with high-performance ingredients and formulation expertise, ICS delivers solutions with the best cost-performance ratios. Its EcoTain label exemplifies its uncompromising pursuit of the principle of environmental sustainability. Sales 2012 (in million CHF) 1,474 Employees 1,750 Production sites 14 R&D Centers 4 Application Development Centers 4 Base Products 24% Industrial Application 33% Consumer Care 43% Sales 2012 by segment LATAM 20% NORAM 15% APAC 14% EMEA 51% Sales 2012 by segment

7 Broad technology platform serves different needs Industrial & Home Care Personal Care Crop Protection Automotive Fluids Aviation Biocides Gas Treatment Construction Defoamers Ethylene Oxide & Derivatives Heat Transfer Fluids Industrial Lubricants Paints & Coatings Special Solvents

8 Segmentation of BU ICS KEY FACTS Sales ICS 2012, mchf 1,474 Consumer Care Sales Share 43% BUSINESS SEGMENTS DIFFERENTIATION BUSINESSES Personal Care Industrial & Home Care Crop Protection Value generated from customer tailored solutions and innovative power Investment in assets, resources and expertise Industrial Application Sales Share 33% ATTRACTIVE NICHES Aviation Construction Engineering* Industrial Biocides Industrial Lubricants Paints & Coatings Value generated from efficiency in sourcing and supply chain Investment to expand footprint and capacities Base Products Sales Share 24% BASE PRODUCTS Ethylene Oxide EO derivatives Amines Softener Quats Sodium Laureth Sulfates Automotive Fluids Value generated from efficiency in sourcing and supply chain Restricted investments

9 Global footprint in production and R&D to support customers growth Manufacturing and R&D Production sites 14 R&D sites 5 Gendorf Frankfurt Santa Clara Clear Lake Mt Holly Tarragona Gebze Shizuoka Zhenjiang Coatzacolacos Maracay Thane Dayabay Tangerang Suzano Zarate

BU Industrial & Consumer Specialties STRATEGY TO SERVE CONSUMER NEEDS IN LINE WITH GLOBAL TRENDS Public Ralf Zerrer BU ICS 16.05.2013

11 To understand the global trends is key for market opportunities Wellbeing and disposable incomes Urbanization Sustainability Growing population/ Emerging markets More people earning better wages & more women entering the workforce will drive the desire for luxury and well-being More hectic lifestyle, less leisure time: changes lifestyle consumption patterns & increases demand for convenient products More than half of the world s population currently lives in cities, by 2030 two third will be urban dwellers With better access to health- and consumer care, life expectancy will remain on the rise Renewable feed stocks as increasing alternative Sustainable processes Biotechnology platforms Population growth: approx. 8.3 bn people will live on planet Earth in 2030. In 2015 the emerging markets will achieve purchasing power parity with the developed world

12 ICS strategy will facilitate focusing on key elements for increasing competitiveness and driving profitable growth Strategic objectives Focus on strengthening its position in consumer markets (Personal Care, Industrial & Home Care, Crop Protection) while keeping its leading position in selected industrial niches. Strategy 1. Refocus operating model in line with nature of business 2. Improve innovation and application know-how 3. Expand regional presence 4. Secure competitive raw material access 5. Focus on core technologies globally

13 Repositioning to strengthen position in key markets From Mixed customer interaction models in multiple consumer and industrial markets Average position in consumer markets Broad product-oriented portfolio and limited application know-how Providing traditional, product-oriented chemistry with focus on global KAs To Operating model tailored to nature of business and leveraging a common technology base Focus on specific customer groups in consumer markets Deep understanding of customer needs by significant investment in expertise and acquisitions. Product development based on provable claims. Portfolio expansion, solution provider to regional accounts, innovation provider to global key accounts Good market position in Europe and Latin America, but minor presence elsewhere Truly global presence based on investments in new regions, especially Asia, Eastern Europe and North America Historically grown technology portfolio with regional gaps Selected sites partially backward integrated into intermediate products Technology strategy driven by assets Global focus on competitive core technologies Cost competitive production of selected commodities based on optimized asset footprint and backward integration into key raw materials Technology strategy driven by market trends

14 Partnerships & acquisitions LATEST INVESTMENTS CUSTOMER BENEFITS Acquisition, October 2011 Oberhausen Technology Center Partnership, August 2011 Kitozyme Acquisition, March 2013. CRM Int. Technology Acquisition Exclusive partnership Technology Acquisition New innovative formulation technology and advanced delivery systems to serve consumer care market Innovative white biotechnology products for personal care applications Natural cosmetic ingredients for sustainable and high performance solutions

15 Going beyond being just natural by smartly combining the technology clusters CRM Olive oil based natural ingredients Take the nature OTC / KitoZyme Encapsulation technology Chitosan derivatives Upgrade by smart technology BU ICS Formulation and skin care expertise Deliver Innovation

BU Industrial & Consumer Specialties PERSONAL CARE Public Ralf Zerrer BU ICS 16.05.2013

17 The global trends are driving the market growth in beauty care Others 6% Oral 9% Fragrances 10% +2.9 +2.1 +7.1 +11.0 +5.8 Hair Care 17% Skin Care 58% +7.1 +1.3 Total 360 bn USD CAGR (%) 2010 2015 by region Source: Euromonitor / Retail value

Personal care 18 Differentiation in the market requires strong claim substantiation From insight to claim support: Work out Reasons-to-Believe (RTB) to support product benefits with appropriate claim substantiation by using new equipment and test capabilities Insight (understand consumer & customer need) Benefit (offer product matching the unmet need come up with solutions) Reason to believe (explain why & how the product is working with state of the art studies)

19 Consumers expect Results from their products Anti-Aging Sensoric Purity Visible Results fighting skin ageing signs Otherwise costly specialty actives are now appearing in more affordable product formulations due to a differentiating consumer Increased Demographic Buying Power and desire to look younger Consumers need to see and feel to reinforce claims. They don t just believe. Sensorics become more important than ever Label Claim Ingredients to be replaced by true ingredients that actually work Consumers make educated choices Professional Skin Care increasing Source: Opportunities in Skin Care: Exploring Specialty Actives, Kline & Company, 2012

20 VitiSpheres : Our new Delivery System Deliver pure actives easily in a stable form Your additional Benefits: Deliver more active quicker and with more effective results Stability of actives Less irritating for consumers Long lasting Ease of formulation (add, stir, ready)

21 Acquisition CRM International complements our portfolio of natural ingredients CRM International is a manufacturer of natural cosmetic ingredients. The product portfolio contains emollients, active ingredients, butters and natural alternatives to silicones. The BU ICS intends to extend innovation capabilities for consumer markets. Besides investing in its own research capabilities, ICS aims to accelerate sustainable solutions based on natural raw materials

22 What is Plantasens? Plantasens offers Clariant s Personal Care product portfolio a new range of all natural ingredients for every cosmetic application, i.e. Skin & Hair care, Sun care and Color cosmetics PRODUCT RANGE Plant-based active ingredients Multi-functional emulsifiers Broad selection of emollients, e.g. vegetable oils, natural & sensorial butters & alternatives to silicone, petrolatum and lanolin Ecocert approved

23 Cosmetic Good Manufacturing Practice (cgmp)as standard to guarantee quality The accreditation of Clariant s global management system with the global ISO 22716 guarantees globally-consistent products and processes. It reinforces our commitment to be a leading partner for the personal care industry. 9 PRODUCTION SITES * COSMETIC INGREDIENTS (GMP) Switzerland: Muttenz (Headquarters) Germany: Gendorf, Frankfurt, Gersthofen Spain: Tarragona China: Zhenjiang Indonesia: Tangerang USA: Mt. Holly, North Carolina Brazil: Suzano Actives: Octopirox, Locron, Vitipure, Zenvivo Emulsifier: Hostacerin, Emulsogen, Hostaphat Emollients & Moisturizer: Velsan, Polyglykol Pearlizer: Genapol Preservatives: Nipagin, Nipaguard Surfactants: Genagen, Hostapon, Genamin * Additional 8 sites are expected to be approved in 2013

EcoTain Sustainable excellence at every step Public Ralf Zerrer BU ICS 16.05.2013

25 The EcoTain values Sustainable design People s health Responsible process Environmental protection Performance & efficiency Conservation of resources Safe & efficient use Ecointegration

26 Major projects and outlook Further significant investments in China in manufacturing and R&D capabilities, shift of selected competence centres to Asia Major projects to enlarge manufacturing capabilities and capacities in North America Investments in Europe in the manufacturing of innovative renewable based surfactants for use in Personal Care and Crop Solutions Investments for the regional markets in South East Asia Continued evaluation of bolt-on acquisition opportunities in order to further strengthen our technology platform

27 Summary Repositioning well under way: strong expertise to provide regional customers and global key account with innovative solutions Innovation: technology strategy driven by market trends, product development based on provable claims Selected bolt on acquisitions to strengthen technology platform Growth platforms in emerging markets have been established Strong global footprint in manufacturing and R&D to support customers globally Significant growth in sales and profitability by consequent implementation of our strategy to continue

Questions & Answers Public Ralf Zerrer BU ICS 16.05.2013